learn Dutasteride
Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Clinical Comparison of Extended-Release Divalproex Versus Delayed-Release Divalproex: Pooled Data Analyses From Nine Trials
Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
research A 6-Month Prospective Study on Efficacy, Safety, and Quality of Life Profiles of Extended-Release Formulation of Valproate in Patients with Epilepsy
Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
research Seizure Control and Side-Effect Profile After Switching Adult Epileptic Patients from Standard to Extended-Release Divalproex Sodium
Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
research Three Months Extended-Release Microspheres Prepared by Multi-Microchannel Microfluidics in Beagle Dog Models
A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
research Effect of Metformin Using 2-Hour Postload Insulin for Measuring Insulin Resistance in Taiwanese Women with Polycystic Ovary Syndrome
Metformin improved insulin resistance and BMI in overweight Taiwanese women with PCOS, and a 2-hour insulin test may be a good screening tool.
Community Join
5 / 164 resultscommunity Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
community Prepare to be disappointed by PP405
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
community People are hyped about PP405 but what about Veradermics phase 2!
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.